The World Health Organization foresees the elimination of HCV infection by 2030. In light of this and the current, nearly worldwide, restriction in direct-acting agents (DAA) accessibility due to their high price, we aimed to evaluate the cost-effectiveness of two alternative DAA treatment policies: Policy 1 (universal): treat all patients, regardless of the fibrosis stage; Policy 2 (prioritized): treat only prioritized patients and delay treatment of the remaining patients until reaching stage F3. The model was based on patient’s data from the PITER cohort. We demonstrated that extending HCV treatment of patients in any fibrosis stage improves health outcomes and is cost-effective.

L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV

S. Rosato;L. Brescini;P. Castelli;S. Castelletti;A. Di Leo;A. Gianstefani;G. Simonetti;G. Verucchi;R. Benigno;C. Torti;F. Quintieri;M. Libanore;D. Segala;E. Salomoni;D. Prati;S. Fargion;E. Calvi;L. Milazzo;L. Bristot;L. Chessa;V. Pastore;G. Borgia;A. Maddaloni;V. Rizzo;P. Angeli;A. Zanetto;M. Cannizzaro;S. Petta;M. Mondelli;A. Cingolani;S. Lam onica;A. Picardi;M. Anselmo;P. De Leo;F. Ridolfi;L. Marinaro;
2018

Abstract

The World Health Organization foresees the elimination of HCV infection by 2030. In light of this and the current, nearly worldwide, restriction in direct-acting agents (DAA) accessibility due to their high price, we aimed to evaluate the cost-effectiveness of two alternative DAA treatment policies: Policy 1 (universal): treat all patients, regardless of the fibrosis stage; Policy 2 (prioritized): treat only prioritized patients and delay treatment of the remaining patients until reaching stage F3. The model was based on patient’s data from the PITER cohort. We demonstrated that extending HCV treatment of patients in any fibrosis stage improves health outcomes and is cost-effective.
2018
Hepatitis C; antiviral therapy; cost-effectiveness
File in questo prodotto:
File Dimensione Formato  
PITER_PUB9.pdf

accesso aperto

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 217.47 kB
Formato Adobe PDF
217.47 kB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2417804
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact